Interstitial lung disease and ANCA-associated vasculitis: a retrospective observational cohort study

被引:115
作者
Arulkumaran, Nishkantha [2 ]
Periselneris, Naomi [2 ]
Gaskin, Gill [2 ]
Strickland, Nicola [3 ]
Ind, Philip W. [4 ]
Pusey, Charles D. [2 ]
Salama, Alan D. [1 ,2 ]
机构
[1] UCL, Royal Free Hosp, Ctr Nephrol, London NW3 2PF, England
[2] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Renal, London, England
[3] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Radiol, London, England
[4] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Resp, Div Med, London, England
关键词
Interstitial lung disease; Anti-neutrophil cytoplasmic antibody; Vasculitis; Microscopic polyangiitis; Mortality; IDIOPATHIC PULMONARY-FIBROSIS; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; RENAL VASCULITIS; MANIFESTATION;
D O I
10.1093/rheumatology/ker236
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. ANCA-associated vasculitis and interstitial lung disease (ILD) are uncommon conditions. The occurrence of both diseases in the same patient is increasingly recognized. Our aim was to ascertain the characteristics and outcomes of patients with ILD and ANCA-associated vasculitis. Methods. A retrospective observational cohort study was performed. Patients who presented to the Hammersmith Hospital, London, with ANCA-associated vasculitis [granulomatosis with polyangiitis (Wegener's), microscopic polyangiitis (MPA) or Churg-Strauss syndrome] who also had ILD were included. Following hospital discharge, all patients were followed up in a multi-disciplinary vasculitis clinic. We recorded patient demographics, diagnostic tests, treatment, complications and mortality. Results. ILD was observed in 2.7% (n = 14) of our patients with ANCA-associated vasculitis (n = 510); all had MPO-ANCA and a clinical diagnosis of MPA, giving a prevalence of 7.2% in patients with MPA (n = 194). There was no significant difference in survival between patients with MPA and ILD and those with MPA alone. Conclusion. It is important that physicians are aware of this clinical association and the presence of ILD should be considered in all patients with ANCA-associated vasculitis, especially those with MPO-ANCA. The possibility that patients with ILD may subsequently develop features of systemic vasculitis should also be remembered.
引用
收藏
页码:2035 / 2043
页数:9
相关论文
共 29 条
[1]  
Amer Thoracic Soc, 2000, AM J RESP CRIT CARE, V161, P646
[2]   Thoracic manifestation of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA)-related disease - CT findings in 51 patients [J].
Ando, Y ;
Okada, F ;
Matsumoto, S ;
Mori, H .
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 2004, 28 (05) :710-716
[3]   Basis of acute exacerbation of idiopathic pulmonary fibrosis in Japanese patients [J].
Azuma, Arata ;
Hagiwara, Koichi ;
Kudoh, Shoji .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 177 (12) :1397-1398
[4]  
Becker-Merok A, 1999, SCAND J RHEUMATOL, V28, P254
[5]   Microscopic polyangiitis presenting as a "Pulmonary-Muscle" syndrome - Is subclinical alveolar hemorrhage the mechanism of pulmonary fibrosis? [J].
Birnbaum, Julius ;
Danoff, Sonye ;
Askin, Frederic B. ;
Stone, John H. .
ARTHRITIS AND RHEUMATISM, 2007, 56 (06) :2065-2071
[6]   Outcome of ANCA-associated renal vasculitis: A 5-year retrospective study [J].
Booth, AD ;
Almond, MK ;
Burns, A ;
Ellis, P ;
Gaskin, G ;
Neild, GH ;
Plaisance, M ;
Pusey, CD ;
Jayne, DRW .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (04) :776-784
[7]   ANTIMYELOPEROXIDASE ANTIBODIES IN PATIENTS WITH RHEUMATOID-ARTHRITIS - PREVALENCE, CLINICAL CORRELATES, AND IGG SUBCLASS [J].
CAMBRIDGE, G ;
WILLIAMS, M ;
LEAKER, B ;
CORBETT, M ;
SMITH, CR .
ANNALS OF THE RHEUMATIC DISEASES, 1994, 53 (01) :24-29
[8]   Pulmonary interstitial fibrosis as a presenting manifestation in perinuclear antineutrophilic cytoplasmic antibody microscopic polyangiitis [J].
Eschun, GM ;
Mink, SN ;
Sharma, S .
CHEST, 2003, 123 (01) :297-+
[9]  
European Respiratory Society, 2002, Am J Respir Crit Care Med, V165, P277, DOI [10.1164/ajrccm.165.2.ats01, DOI 10.1164/AJRCCM.165.2.ATS01]
[10]   Antimyeloperoxidase-associated lung disease - An experimental model [J].
Foucher, P ;
Heeringa, P ;
Petersen, AH ;
Huitema, MG ;
Brouwer, E ;
Tervaert, JWC ;
Prop, J ;
Camus, P ;
Weening, FJ ;
Kallenberg, CGM .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 160 (03) :987-994